The loss of patent coverage of products on the market will cost Big Pharma about 100 billion dollars over the next 5 years, while the value that soon-to-be-introduced medicines will bring to the market will be limited to 30 billion. These are the estimates of Nils Behnke, partner of the consulting firm Bain & Company. Four main strategies currently followed by pharmaceutical companies to meet these forecasts: expand the R&D pipeline also thanks to outsourcing; expand into emerging markets; increase sales of non-patented products as well; experiment with new pricing strategies in different countries.
The Financial Times Pg.10 – 13/05/2010 
